QHSLab (OTCMKTS:USAQ – Get Free Report) and Coloplast A/S (OTCMKTS:CLPBY – Get Free Report) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, valuation and risk.
Profitability
This table compares QHSLab and Coloplast A/S’s net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
QHSLab | -15.33% | N/A | -21.37% |
Coloplast A/S | 14.61% | 24.67% | 8.52% |
Volatility & Risk
QHSLab has a beta of 0.44, suggesting that its stock price is 56% less volatile than the S&P 500. Comparatively, Coloplast A/S has a beta of 0.34, suggesting that its stock price is 66% less volatile than the S&P 500.
Earnings and Valuation
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
QHSLab | $2.13 million | 0.45 | -$260,000.00 | ($0.04) | -2.25 |
Coloplast A/S | $3.93 billion | N/A | $734.56 million | $0.27 | 31.70 |
Coloplast A/S has higher revenue and earnings than QHSLab. QHSLab is trading at a lower price-to-earnings ratio than Coloplast A/S, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a breakdown of recent ratings and price targets for QHSLab and Coloplast A/S, as provided by MarketBeat.com.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
QHSLab | 0 | 0 | 0 | 0 | 0.00 |
Coloplast A/S | 0 | 4 | 0 | 1 | 2.40 |
Summary
Coloplast A/S beats QHSLab on 9 of the 10 factors compared between the two stocks.
About QHSLab
QHSLab, Inc., a medical device technology and software as a service (SaaS) company, focuses on value-based healthcare, informatics, and algorithmic personalized medicine. It develops digital therapeutics and point of care solutions to support remote patient monitoring, address chronic care, and preventive medicine. The company provides quality health score lab expert system (QHSLab), a cloud-based SaaS system, which provides physicians and healthcare organizations with the ability to capture and store patient information electronically in a secure database; and distributes AllergiEnd, a diagnostic related product and allergen immunotherapy treatments to primary care physicians. Its products are designed to promote prevention, early detection, management, and reversal of chronic diseases. The company was formerly known as USA Equities Corp. and changed its name to QHSLab, Inc. in April 2022. QHSLab, Inc. has a strategic alliance with Medical License Factory, LLC. QHSLab, Inc. was incorporated in 1983 and is based in West Palm Beach, Florida.
About Coloplast A/S
Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; and Peristeen Plus, a transanal irrigation system. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand; and skin care products that include cleansers, moisturizers, skin protectants, antifungal products, and hand cleansers, as well as InterDry, a skin fold management solution. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Additionally, its voice and respiratory care solutions include laryngectomy care products comprising Provox, a voice prosthesis for speaking, HMEs, adhesives, laryngectomy tubes for breathing, devices for speaking hands-free, and accessories, as well as tracheostomy care products under Tracoe brand. The company was founded in 1954 and is headquartered in Humlebæk, Denmark.
Receive News & Ratings for QHSLab Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for QHSLab and related companies with MarketBeat.com's FREE daily email newsletter.